Relay Therapeutics Full Year 2023 Earnings: Beats Expectations [Yahoo! Finance]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Yahoo! Finance
Net loss: US$342.0m (loss widened by 18% from FY 2022). US$2.79 loss per share (further deteriorated from US$2.59 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Relay Therapeutics Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) also surpassed analyst estimates by 3.0%. Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 7.7% from a week ago. Risk Analysis Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Relay Therapeutics (1 makes us a bit uncomfortable) you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. Th
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024GlobeNewswire
- Relay Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Relay Therapeutics: Platform More Important Than Programs [Seeking Alpha]Seeking Alpha
- Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.MarketBeat
- Relay Therapeutics to Participate in Three Upcoming Investor ConferencesGlobeNewswire
RLAY
Earnings
- 2/22/24 - Beat
RLAY
Analyst Actions
- 2/22/24 - Stifel
RLAY
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- RLAY's page on the SEC website